{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:30:44Z","timestamp":1774737044443,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020555","name":"Intas Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejps.2022.106248","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T21:10:38Z","timestamp":1656450638000},"page":"106248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx\u00ae: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer"],"prefix":"10.1016","volume":"176","author":[{"given":"Prakash S.","family":"S\uff0e","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajnish Vasant","family":"Nagarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna Chaitanya","family":"Puligundla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh K.","family":"N\uff0e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh Reddy","family":"Boya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit Baldevbhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lovenish","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniket","family":"Thoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar Gordhanbhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay Omprakash","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghanshyam Nanubhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujtaba A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2022.106248_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejps.2022.106248_bib0002","article-title":"Bioequivalence study of pegylated doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL\u00ae in ovarian cancer patients: physicochemical characterization and pre-clinical studies","volume":"7","author":"Ali","year":"2016","journal-title":"J. Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejps.2022.106248_bib0003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-018-3643-3","article-title":"Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil\u00ae or Caelyx\u00ae in advanced ovarian cancer","volume":"82","author":"Bhowmik","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2022.106248_bib0004","series-title":"Summary of Product Characteristics. Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium","article-title":"Caelyx pegylated liposomal 2 mg\/ml concentrate for solution for infusion","year":"2006"},{"key":"10.1016\/j.ejps.2022.106248_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0304-3835(88)90113-9","article-title":"The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells","volume":"41","author":"Cervantes","year":"1988","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2022.106248_bib0006","series-title":"for intravenous use. Prescribing Information","article-title":"DOXIL (doxorubicin hydrochloride liposome injection)","year":"2019"},{"key":"10.1016\/j.ejps.2022.106248_bib0007","series-title":"European Medicines Agency. Caelyx: EPAR-Procedural Steps Taken Before Authorisation","year":"2012"},{"key":"10.1016\/j.ejps.2022.106248_bib0008","series-title":"Committee for Medicinal Products for Human Use (CHMP). Pegylated Liposomal Doxorubicin Hydrochloride Concentrate for Solution 2 mg\/ml Product-Specific Bioequivalence Guidance. EMA\/CHMP\/800775\/2017","year":"2018"},{"key":"10.1016\/j.ejps.2022.106248_bib0009","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1208\/s12248-012-9382-1","article-title":"Bioequivalence requirements in the European Union: critical discussion","volume":"14","author":"Garc\u00eda-Arieta","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2022.106248_bib0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/153303460800700611","article-title":"Recent advances in protection against doxorubicin-induced toxicity","volume":"7","author":"Injac","year":"2008","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ejps.2022.106248_bib0011","series-title":"PubChem Compound Summary for CID 31703, Doxorubicin","article-title":"National Center for Biotechnology Information","year":"2022"},{"key":"10.1016\/j.ejps.2022.106248_bib0012","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2022.106248_bib0013","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ejps.2022.106248_bib0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0272989X04273139","article-title":"Impact of generic drug entry on cost-effectiveness analysis","volume":"25","author":"Shih","year":"2005","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ejps.2022.106248_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLM.2008.n.001","article-title":"Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin","volume":"8","author":"Soloman","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.ejps.2022.106248_bib0016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.ejps.2022.106248_bib0017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejps.2022.106248_bib0018","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2022.106248_bib0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF03192321","article-title":"The existence of sequence effect in cross-over bioequivalence trials","volume":"25","author":"Zintzaras","year":"2000","journal-title":"Eur. J. Drug Metab. Pharmacokinet."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722001336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722001336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:04:18Z","timestamp":1760529858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":19,"alternative-id":["S0928098722001336"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106248","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx\u00ae: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106248"}}